ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers

Adam S. Kibel, MD
Published: Saturday, Jan 09, 2016



Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists regarding the field of genitourinary malignancies.

Community oncologists should focus on the results of the STAMPEDE and CHAARTED studies, which demonstrate level one evidence that patients with newly diagnosed metastatic prostate cancer who receive docetaxel in combination with androgen deprivation therapy (ADT) have a significant overall survival benefit. With this regimen, the life expectancy is increased from 1 year to nearly 1.5 years, Kibel explains.

Secondly, it is important to treat patients who develop bone metastases, he adds. The number of skeletal events decreases when patients receive docetaxel and ADT, and they will also have an improved quality of life.

<<< View more from the 2016 GU Cancer Symposium



Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists regarding the field of genitourinary malignancies.

Community oncologists should focus on the results of the STAMPEDE and CHAARTED studies, which demonstrate level one evidence that patients with newly diagnosed metastatic prostate cancer who receive docetaxel in combination with androgen deprivation therapy (ADT) have a significant overall survival benefit. With this regimen, the life expectancy is increased from 1 year to nearly 1.5 years, Kibel explains.

Secondly, it is important to treat patients who develop bone metastases, he adds. The number of skeletal events decreases when patients receive docetaxel and ADT, and they will also have an improved quality of life.

<<< View more from the 2016 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x